×
QQQ   283.80 (+0.09%)
AAPL   139.23 (+1.30%)
MSFT   260.26 (+1.47%)
META   163.94 (+2.03%)
GOOGL   2,234.03 (-0.27%)
AMZN   108.92 (+1.42%)
TSLA   685.47 (-1.79%)
NVDA   155.42 (-2.75%)
NIO   21.86 (-2.24%)
BABA   116.03 (-0.63%)
AMD   77.99 (-3.45%)
MU   56.02 (-3.18%)
CGC   3.50 (-3.05%)
T   20.95 (+1.65%)
GE   63.69 (-3.32%)
F   11.52 (-2.46%)
DIS   95.65 (-0.28%)
AMC   13.65 (+2.02%)
PFE   50.94 (+0.55%)
PYPL   71.47 (-0.49%)
NFLX   178.36 (-0.69%)
QQQ   283.80 (+0.09%)
AAPL   139.23 (+1.30%)
MSFT   260.26 (+1.47%)
META   163.94 (+2.03%)
GOOGL   2,234.03 (-0.27%)
AMZN   108.92 (+1.42%)
TSLA   685.47 (-1.79%)
NVDA   155.42 (-2.75%)
NIO   21.86 (-2.24%)
BABA   116.03 (-0.63%)
AMD   77.99 (-3.45%)
MU   56.02 (-3.18%)
CGC   3.50 (-3.05%)
T   20.95 (+1.65%)
GE   63.69 (-3.32%)
F   11.52 (-2.46%)
DIS   95.65 (-0.28%)
AMC   13.65 (+2.02%)
PFE   50.94 (+0.55%)
PYPL   71.47 (-0.49%)
NFLX   178.36 (-0.69%)
QQQ   283.80 (+0.09%)
AAPL   139.23 (+1.30%)
MSFT   260.26 (+1.47%)
META   163.94 (+2.03%)
GOOGL   2,234.03 (-0.27%)
AMZN   108.92 (+1.42%)
TSLA   685.47 (-1.79%)
NVDA   155.42 (-2.75%)
NIO   21.86 (-2.24%)
BABA   116.03 (-0.63%)
AMD   77.99 (-3.45%)
MU   56.02 (-3.18%)
CGC   3.50 (-3.05%)
T   20.95 (+1.65%)
GE   63.69 (-3.32%)
F   11.52 (-2.46%)
DIS   95.65 (-0.28%)
AMC   13.65 (+2.02%)
PFE   50.94 (+0.55%)
PYPL   71.47 (-0.49%)
NFLX   178.36 (-0.69%)
QQQ   283.80 (+0.09%)
AAPL   139.23 (+1.30%)
MSFT   260.26 (+1.47%)
META   163.94 (+2.03%)
GOOGL   2,234.03 (-0.27%)
AMZN   108.92 (+1.42%)
TSLA   685.47 (-1.79%)
NVDA   155.42 (-2.75%)
NIO   21.86 (-2.24%)
BABA   116.03 (-0.63%)
AMD   77.99 (-3.45%)
MU   56.02 (-3.18%)
CGC   3.50 (-3.05%)
T   20.95 (+1.65%)
GE   63.69 (-3.32%)
F   11.52 (-2.46%)
DIS   95.65 (-0.28%)
AMC   13.65 (+2.02%)
PFE   50.94 (+0.55%)
PYPL   71.47 (-0.49%)
NFLX   178.36 (-0.69%)
NASDAQ:VSTM

Verastem Stock Forecast, Price & News

$1.20
+0.05 (+4.35%)
(As of 06/29/2022 04:00 PM ET)
Add
Compare
Today's Range
$1.12
$1.22
50-Day Range
$1.02
$1.58
52-Week Range
$1.00
$4.17
Volume
1.22 million shs
Average Volume
2.21 million shs
Market Capitalization
$223.63 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$5.50
30 days | 90 days | 365 days | Advanced Chart

Receive VSTM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Verastem and its competitors with MarketBeat's FREE daily newsletter.

VSTM Stock Forecast (MarketRank)

Overall MarketRank

2.23 out of 5 stars

Medical Sector

351st out of 1,432 stocks

Pharmaceutical Preparations Industry

150th out of 685 stocks

Analyst Opinion: 3.5Community Rank: 4.5Dividend Strength: 0.0Insider Behavior: 2.5Valuation: 0.6 5 -4 -3 -2 -1 -
Verastem logo

About Verastem (NASDAQ:VSTM)

Verastem, Inc., a development-stage biopharmaceutical company, focusing on developing and commercializing drugs for the treatment of cancer. Its product in development includes VS-6766, a dual rapidly accelerated fibrosarcoma (RAF)/mitogen-activated protein kinase (MEK) clamp that blocks MEK kinase activity and the ability of RAF to phosphorylate MEK. The company also engages in developing RAMP 201, an adaptive two-part multicenter, parallel cohort, randomized open label trial to evaluate the efficacy and safety of VS-6766 and in combination with defactinib, an oral small molecule inhibitor of focal adhesion kinase (FAK) in patients with recurrent low grade serous ovarian cancer; and RAMP 202, which is in Phase 2 trial to evaluate the safety of VS-6766 in combination with defactinib in patients with KRAS and BRAF mutant non-small cell lung cancer following treatment with a platinum-based regimen and immune checkpoint inhibitor. Verastem, Inc. has license agreements with Chugai Pharmaceutical Co., Ltd. for the development, commercialization, and manufacture of products containing VS-6766; and Pfizer Inc. to research, develop, manufacture, and commercialize products containing Pfizer's inhibitors of FAK for therapeutic, diagnostic and prophylactic uses in humans. In addition, it has clinical collaboration agreement with Amgen, Inc. to evaluate the combination of VS-6766 with Amgen's KRAS-G12C inhibitor LUMAKRASTM which in Phase 1/2 trial entitled RAMP 203. The company was incorporated in 2010 and is headquartered in Needham, Massachusetts.

VSTM Stock News Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
Biotechnology
Sector
Medical
Current Symbol
NASDAQ:VSTM
CUSIP
92337C10
Fax
N/A
Employees
48
Year Founded
N/A

Company Calendar

Last Earnings
5/09/2022
Today
6/29/2022
Next Earnings (Estimated)
8/01/2022
Fiscal Year End
12/31/2022

Price Target and Rating

Average Stock Price Forecast
$5.50
High Stock Price Forecast
$6.00
Low Stock Price Forecast
$5.00
Forecasted Upside/Downside
+358.3%
Consensus Rating
Buy
Rating Score (0-4)
3
Research Coverage
5 Analysts

Profitability

Net Income
$-71.20 million
Net Margins
-2,007.44%
Pretax Margin
-2,007.44%

Debt

Sales & Book Value

Annual Sales
$2.05 million
Book Value
$0.48 per share

Miscellaneous

Free Float
180,397,000
Market Cap
$223.63 million
Optionable
Optionable
Beta
0.89














Verastem Frequently Asked Questions

Should I buy or sell Verastem stock right now?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Verastem in the last year. There are currently 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Verastem stock.
View analyst ratings for Verastem
or view top-rated stocks.

What is Verastem's stock price forecast for 2022?

5 analysts have issued 1 year price objectives for Verastem's stock. Their VSTM stock forecasts range from $5.00 to $6.00. On average, they expect Verastem's stock price to reach $5.50 in the next year. This suggests a possible upside of 358.3% from the stock's current price.
View analysts' price targets for Verastem
or view top-rated stocks among Wall Street analysts.

How has Verastem's stock performed in 2022?

Verastem's stock was trading at $2.05 at the beginning of the year. Since then, VSTM stock has decreased by 41.5% and is now trading at $1.20.
View the best growth stocks for 2022 here
.

When is Verastem's next earnings date?

Verastem is scheduled to release its next quarterly earnings announcement on Monday, August 1st 2022.
View our earnings forecast for Verastem
.

How were Verastem's earnings last quarter?

Verastem, Inc. (NASDAQ:VSTM) announced its earnings results on Monday, May, 9th. The biopharmaceutical company reported ($0.09) EPS for the quarter, missing the consensus estimate of ($0.08) by $0.01. The biopharmaceutical company had revenue of $2.60 million for the quarter, compared to analyst estimates of $2.50 million. Verastem had a negative trailing twelve-month return on equity of 84.99% and a negative net margin of 2,007.44%.
View Verastem's earnings history
.

Who are Verastem's key executives?

Verastem's management team includes the following people:
  • Mr. Brian M. Stuglik BPHARM, R.Ph., RPh, CEO & Director (Age 63, Pay $1.04M)
  • Mr. Daniel W. Paterson, COO & Pres (Age 61, Pay $710.39k)
  • Mr. Robert E. Gagnon, Chief Bus. & Financial Officer (Age 48, Pay $609.39k) (LinkedIn Profile)
  • Mr. Richard H. Aldrich M.B.A., Mba, Founder and Consultant (Age 68)
  • Dr. Robert A. Weinberg Ph.D., Co-Founder & Chair of Scientific Advisory Board
  • Dr. Piyush B. Gupta Ph.D., Co-Founder
  • Dr. Michelle Dipp M.D., Ph.D., Co-Founder (Age 46)
  • Dr. Jonathan Pachter Ph.D., Chief Scientific Officer (Age 64)
  • Ms. Erin S. Cox, Sr. Director of Investor Relations & Corp. Communications
  • Mr. Sean C. Flynn, VP, Gen. Counsel & Sec. (Age 48)

What is Robert Forrester's approval rating as Verastem's CEO?

11 employees have rated Verastem CEO Robert Forrester on Glassdoor.com. Robert Forrester has an approval rating of 100% among Verastem's employees. This puts Robert Forrester in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Verastem own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Verastem investors own include TherapeuticsMD (TXMD), Micron Technology (MU), Novavax (NVAX), Inovio Pharmaceuticals (INO), Gilead Sciences (gild), Sorrento Therapeutics (SRNE), SCYNEXIS (SCYX), TG Therapeutics (TGTX), Amarin (AMRN) and Viking Therapeutics (VKTX).

What is Verastem's stock symbol?

Verastem trades on the NASDAQ under the ticker symbol "VSTM."

Who are Verastem's major shareholders?

Verastem's stock is owned by a variety of retail and institutional investors. Top institutional investors include BlackRock Inc. (6.54%), Vanguard Group Inc. (4.72%), Eagle Asset Management Inc. (2.48%), State Street Corp (1.67%), Dimensional Fund Advisors LP (1.00%) and Renaissance Technologies LLC (0.90%). Company insiders that own Verastem stock include Brian M Stuglik, Dan Paterson, Ra Capital Management, LP, Robert E Gagnon and Timothy J Barberich.
View institutional ownership trends for Verastem
.

Which major investors are selling Verastem stock?

VSTM stock was sold by a variety of institutional investors in the last quarter, including State Street Corp, Panagora Asset Management Inc., Dimensional Fund Advisors LP, Bank of America Corp DE, UBS Group AG, Acadian Asset Management LLC, ClariVest Asset Management LLC, and Raymond James & Associates. Company insiders that have sold Verastem company stock in the last two years include Brian M Stuglik, Dan Paterson, and Robert E Gagnon.
View insider buying and selling activity for Verastem
or view top insider-selling stocks.

Which major investors are buying Verastem stock?

VSTM stock was bought by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Eagle Asset Management Inc., Ergoteles LLC, Wetherby Asset Management Inc., Goldman Sachs Group Inc., Hsbc Holdings PLC, Samalin Investment Counsel LLC, and XTX Topco Ltd.
View insider buying and selling activity for Verastem
or or view top insider-buying stocks.

How do I buy shares of Verastem?

Shares of VSTM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Verastem's stock price today?

One share of VSTM stock can currently be purchased for approximately $1.20.

How much money does Verastem make?

Verastem (NASDAQ:VSTM) has a market capitalization of $223.63 million and generates $2.05 million in revenue each year. The biopharmaceutical company earns $-71.20 million in net income (profit) each year or ($0.41) on an earnings per share basis.

How many employees does Verastem have?

Verastem employs 48 workers across the globe.

How can I contact Verastem?

Verastem's mailing address is 117 KENDRICK STREET SUITE 500, NEEDHAM MA, 02494. The official website for Verastem is www.verastem.com. The biopharmaceutical company can be reached via phone at (781) 292-4200 or via email at [email protected].

This page (NASDAQ:VSTM) was last updated on 6/29/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer.